In Boston on August 14, 2026, Cue Biopharma, Inc. (Nasdaq: CUE), a company in the clinical stage of biopharmaceuticals focusing on innovative treatments for immune-related illnesses, disclosed its financial performance for the second quarter of 2026 along with notable recent accomplishments.